11/20
10:24 am
halo
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $68.00 price target on the stock.
Low
Report
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $68.00 price target on the stock.
11/1
08:36 am
halo
Rating for HALO
Low
Report
Rating for HALO
11/1
08:36 am
halo
Rating for HALO
Low
Report
Rating for HALO
10/25
08:37 am
halo
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
Low
Report
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
10/7
12:29 pm
halo
Rating for HALO
Low
Report
Rating for HALO
10/7
12:29 pm
halo
Rating for HALO
Low
Report
Rating for HALO
10/7
09:08 am
halo
Halozyme Therapeutics, Inc. (NASDAQ: HALO) was downgraded by analysts at Wells Fargo & Company from an "overweight" rating to an "equal weight" rating. They now have a $62.00 price target on the stock, up previously from $58.00.
Medium
Report
Halozyme Therapeutics, Inc. (NASDAQ: HALO) was downgraded by analysts at Wells Fargo & Company from an "overweight" rating to an "equal weight" rating. They now have a $62.00 price target on the stock, up previously from $58.00.
10/4
08:06 am
halo
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
Low
Report
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
9/19
09:06 am
halo
Rating for HALO
Medium
Report
Rating for HALO
9/19
07:58 am
halo
Halozyme Therapeutics, Inc. (NASDAQ: HALO) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating. They now have a $57.00 price target on the stock, up previously from $52.00.
Medium
Report
Halozyme Therapeutics, Inc. (NASDAQ: HALO) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating. They now have a $57.00 price target on the stock, up previously from $52.00.
9/13
08:02 am
halo
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
Low
Report
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.